mTOR inhibition and erythropoiesis : microcytosis or anaemia ?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.

  2010cited by this paper
• Anaemia, microcytosis and sirolimus--is iron the missing link?

  2010cited by this paper
• A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

  2010cited by this paper
• A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

  2009cited by this paper
• Reduction in Erythropoietin Resistance After Conversion From Sirolimus to Enteric Coated Mycophenolate Sodium

  2008cited by this paper
• Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.

  2007cited by this paper
• Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients.

  2007cited by this paper
• Incidence of anemia in sirolimus‐treated renal transplant recipients: the importance of preserving renal function *

  2007cited by this paper
• Sirolimus Interferes with Iron Homeostasis in Renal Transplant Recipients

  2006cited by this paper
• Marked erythrocyte microcytosis under primary immunosuppression with sirolimus

  2006cited by this paper
• Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors

  2006influential reference
• Anemia after Late Introduction of Sirolimus May Correlate with Biochemical Evidence of a Chronic Inflammatory State

  2005cited by this paper
• Impact of Diabetic Status on Mycophenolic Acid (MPA) Exposure Using Mycophenolate Mofetil (MMF) in De Novo Renal Transplant Patients.

  2004cited by this paper
• Comparative Effects of Sirolimus and Mycophenolate Mofetil on Erythropoiesis in Kidney Transplant Patients

  2004cited by this paper
• Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.

  2001cited by this paper
• Determination of erythrocyte life span in F-344, Wistar, and Sprague-Dawley rats using a modification of the [3H]diisopropylfluorophosphate ([3H]DFP) method.

  1987cited by this paper

• Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1

  2025cites this paper
• The Link between Iron Turnover and Pharmacotherapy in Transplant Patients

  2023cites this paper
• Branched-chain amino acids are linked with iron metabolism

  2020cites this paper
• Preeclampsia is Associated with Sex-Specific Transcriptional and Proteomic Changes in Fetal Erythroid Cells

  2019cites this paper
• Investigating the source of free fetal hemoglobin in preeclampsia. The role of the placenta and the fetus.

  2018cites this paper
• Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians

  2018cites this paper
• miR-144/451 represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia

  2017cites this paper
• Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator‐initiated prospective study

  2017cites this paper
• Safety of mTOR inhibitors in adult solid organ transplantation

  2016cites this paper
• Spectrum of anemia after kidney transplantation: pathophysiology and therapeutic implications

  2016cites this paper
• The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability

  2015cites this paper
• A critical role for mTORC1 in erythropoiesis and anemia

  2014cites this paper
• The pros and the cons of mTOR inhibitors in kidney transplantation

  2014cites this paper
• Longevity, aging and rapamycin

  2014cites this paper
• mTOR inhibitors and renal allograft: Yin and Yang

  2014cites this paper
• FOXO3‐mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis

  2014cites this paper
• Strategies for the management of adverse events associated with mTOR inhibitors.

  2014cites this paper
• Rapamycin extends murine lifespan but has limited effects on aging.

  2013cites this paper
• Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors

  2013cites this paper
• An evaluation of sirolimus in renal transplantation

  2012cites this paper